Cyclopharm Ltd (ASX: CYC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Cyclopharm Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $146.94 million
P/E Ratio N/A
Dividend Yield 0.31%
Shares Outstanding 94.19 million
Earnings per share -0.051
Dividend per share 0.01
Year To Date Return -16.88%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Cyclopharm Ltd (ASX: CYC)
    Latest News

    A young family with two kids smiling as they look out the window of an apartment they just bought
    Share Market News

    ASX shares vs. property: The opportunities in 2024

    Four property markets are 'in favour of buyers' while mining stocks look hot for 2024, say these experts.

    Read more »

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Share Gainers

    Why CSL, Cyclopharm, Dicker Data, and Fletcher Building shares are pushing higher

    These ASX shares are starting the week on a positive note.

    Read more »

    A group of business people dance around the office looking very happy.
    Share Gainers

    Can you guess the top 3 performing All Ordinaries shares in the first week of trade?

    All three suffered heavy losses in 2022. Could some bargain hunting be in play?

    Read more »

    four excited doctors with their hands in the air
    Share Gainers

    Cyclopharm (ASX:CYC) share price jumps on trading update

    Today's gains will be welcome news for shareholders after major Monday's selloff.

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    Healthcare Shares

    Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower

    Some disappointing news from the FDA is sending investors running for the hills.

    Read more »

    woman in lab coat conducting testing representing biotech
    Healthcare Shares

    Why is the Cyclopharm (ASX:CYC) share price down today?

    The Cyclopharm Limited (ASX: CYC) share price dropped today after the company released its 2021 AGM Presentation.

    Read more »

    Share Market News

    Why the Cyclopharm (ASX:CYC) share price popped 6% today

    The Cyclopharm share price went soaring today as the company announced a market update. We take a closer look.

    Read more »

    Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today
    Share Market News

    Why the Cyclopharma (ASX:CYC) share price surged to record high today

    The Cyclopharm Limited (ASX: CYC) share price continues to bask in the glory of its clinical trial announcement released earlier…

    Read more »


    Cyclopharm share price rockets 22% higher on FDA application approval

    The Cyclopharm Limited (ASX: CYC) share price rocketed out of the gates this morning after the company revealed it is one…

    Read more »

    a woman
    ⏸️ Investing

    3 speculative micro-cap shares that could make you a fortune

    Here are three sub $100 million companies with huge growth potential.

    Read more »

    a woman
    ⏸️ Investing

    3 cheap diversified micro-cap stocks for your portfolio

    Could these three companies deliver impressive gains for your portfolio?

    Read more »

    a woman
    ⏸️ Investing

    10 stocks up by more than 50% in the past month

    The market has gone nowhere in the past month, but these 10 stocks are up by more than 50%

    Read more »

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    01 Sep 2023 $0.0050 0.00% Interim 11 Sep 2023
    27 Mar 2023 $0.0050 0.00% Final 04 Apr 2023
    02 Sep 2022 $0.0050 0.00% Interim 12 Sep 2022
    04 Apr 2022 $0.0050 0.00% Final 12 Apr 2022
    03 Sep 2021 $0.0050 0.00% Interim 13 Sep 2021
    01 Apr 2021 $0.0050 0.00% Final 13 Apr 2021
    04 Sep 2020 $0.0050 0.00% Interim 14 Sep 2020
    30 Mar 2020 $0.0050 0.00% Final 07 Apr 2020
    06 Sep 2019 $0.0050 0.00% Interim 16 Sep 2019
    05 Apr 2019 $0.0050 0.00% Final 15 Apr 2019
    07 Sep 2018 $0.0050 0.00% Interim 17 Sep 2018
    06 Apr 2018 $0.0050 0.00% Final 16 Apr 2018
    01 Sep 2017 $0.0000 0.00% Interim 11 Sep 2017
    31 Mar 2017 $0.0050 0.00% Final 10 Apr 2017
    02 Sep 2016 $0.0050 46.00% Interim 12 Sep 2016
    11 Apr 2016 $0.0050 100.00% Interim 19 Apr 2016

    CYC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Cyclopharm Ltd

    Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals tobe used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

    CYC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 May 2024 $1.56 $-0.04 -2.50% 28,687 $1.62 $1.64 $1.54
    17 May 2024 $1.60 $-0.05 -3.03% 10,545 $1.62 $1.62 $1.60
    16 May 2024 $1.65 $-0.02 -1.20% 8,627 $1.70 $1.70 $1.65
    15 May 2024 $1.67 $0.00 0.00% 7,020 $1.70 $1.70 $1.67
    14 May 2024 $1.67 $-0.03 -1.76% 13,042 $1.72 $1.73 $1.67
    13 May 2024 $1.70 $-0.02 -1.16% 66,945 $1.74 $1.79 $1.70
    10 May 2024 $1.72 $0.01 0.58% 3,297 $1.73 $1.73 $1.72
    09 May 2024 $1.71 $-0.09 -5.01% 16,935 $1.80 $1.80 $1.70
    08 May 2024 $1.80 $0.08 4.65% 19,463 $1.66 $1.80 $1.65
    07 May 2024 $1.72 $-0.01 -0.58% 34,449 $1.74 $1.74 $1.66
    06 May 2024 $1.73 $-0.07 -3.89% 32,866 $1.80 $1.80 $1.73
    02 May 2024 $1.80 $0.05 2.86% 2,610,663 $1.77 $1.80 $1.76
    30 Apr 2024 $1.75 $-0.01 -0.57% 16,847 $1.78 $1.78 $1.75
    29 Apr 2024 $1.76 $0.01 0.57% 7,385 $1.79 $1.79 $1.75
    26 Apr 2024 $1.75 $0.00 0.00% 220 $1.75 $1.75 $1.75
    24 Apr 2024 $1.75 $-0.03 -1.69% 18,513 $1.77 $1.77 $1.75
    22 Apr 2024 $1.78 $0.00 0.00% 12,000 $1.80 $1.80 $1.77

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 Nov 2023 James McBrayer Exercise 200,000 $262,000
    Exercise of options. estimated value
    30 Nov 2023 James McBrayer Buy 200,000 $262,000
    Exercise of options. estimated value
    01 Nov 2023 Kevin Barrow Buy 1,000 $1,960
    On-market trade.
    31 Oct 2023 David Heaney Buy 10,000 $20,400
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David James Heaney Non-Executive DirectorNon-Executive Chairman Nov 2006
    Mr Heaney was appointed to the Cyclopharm Board on 20 November 2006 and is currently the Chairman of Cyclopharm and Chairman of the Remuneration and Board Nomination Committees. He was formerly Chairman of the Audit and Risk Committee until 28 February 2019. Mr Heaney was re appointed as acting Chairman of the Audit and Risk Committee effective 1 December 2021 until 18 February 2024. Mr Heaney has also served as a Non Executive Director of a number of ASX listed and non listed companies. Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.
    Ms Dianne Margaret Angus Non-Executive Director Aug 2021
    Ms Angus was appointed to the Board on 10 August 2021. She is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialisation in these industries, notably including the clinical validation of therapeutics to create asset valuation uplift. Ms Angus has wide expertise in corporate strategy and innovative product development together with governance and compliance in listed capital markets.
    Mr James S McBrayer Chief Executive OfficerManaging DirectorCompany Secretary Jun 2008
    Mr McBrayer has been a member of the Board since 3 June 2008 at which time he accepted the role of Managing Director. Mr McBrayer serves as a member of the Board Nominations Committee. Mr McBrayer has more than 30 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals, Australia's largest contract manufacturer of over the counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's largest radioactive diagnostic and therapeutic pharmaceutical provider.
    Mr Kevin Michael John Barrow Non-Executive Director Sep 2022
    Mr Barrow was appointed to the Board on 1 September 2022. He is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Mr Barrow holds a Master of Science (with 1st Class Honours) from Waikato University, New Zealand. He obtained an MBA from the Macquarie Graduate School of Management, Sydney, Australia and is a graduate of the Australian Institute of Company Directors and an Adjunct Fellow at Macquarie University. He brings to the Cyclopharm board more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles.
    Mr Gregory George King Non-Executive Director Sep 2022
    Dr King is Professor of Respiratory Medicine at the Northern and Central Clinical Schools of the University of Sydney. He is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney.
    Mr John Wigglesworth Non-Executive Director Feb 2024
    Mr Wigglesworth brings with him 37 years of professional experience, including nearly 25 years as a Partner at KPMG. His background as a Chartered Accountant and Company Director, coupled with his industry experience. Mr Wigglesworths career include a company director having held several previous Board positions over the past decade including Atlas Arteria Limited (ASX:ALX) and also in public sector health entities, While at KPMG John advised and supported many Australian and international multinational companies during periods of international growth., Held various KPMG leadership positions including serving as a member of the Audit Leadership Group and National leader of KPMG Audits Retention & Conversion function, managing proposals, client relationship management, and global management groups/committees, Expertise in ASX listing readiness, IPOs, and business transition, working closely with companies navigating the challenges of transitioning to a listed entity, Financial reporting and market communications, on ASX and regulatory reporting along with financial reporting matters. He has experience in risk management, including Cyber, and serving as Chairman of the Audit & Risk Committee at both Atlas Arteria Limited and Macquarie University.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Anglo Australian Christian and Charitable Fund 13,211,332 14.04%
    Barings Acceptance Limited 11,444,962 12.16%
    HSBC Custody Nominees (Australia) Limited A/c 2 9,754,594 10.37%
    National Nominees Limited 9,706,764 10.32%
    Chemical Overseas Limited 8,005,769 8.51%
    CVC Limited 6,644,758 7.06%
    Citicorp Nominees Pty Limited 3,893,748 4.14%
    McBrayer Reid Investments Pty Ltd LTIP 6 1,721,554 1.83%
    Chemical Overseas Limited II 1,182,239 1.26%
    UBS Nominees Pty Ltd 1,111,535 1.18%
    Mr James McBrayer 1,061,728 1.13%
    Phillips River Pty Ltd <GAT A/c> 1,038,914 1.10%
    Lloyds & Casanove Investment Partners Ltd 987,503 1.05%
    Mr James McBrayer II 861,728 0.92%
    South Seas Holdings Pty Limited 686,538 0.73%
    City & Westminster Limited 556,327 0.59%
    Mathew Farag <LTIP Account Holding 4> 500,000 0.53%
    McBrayer Reid Investments Pty Limited 500,000 0.53%
    Marayong Nicholas Pty Ltd 431,758 0.46%
    Marayong Nicholas Pty Ltd II 425,000 0.45%